Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19

被引:5
作者
Tunjungputri, Rahajeng N. [1 ,2 ]
Tetrasiwi, Erpryta Nurdia [1 ,2 ]
Veronica, Merlinda [1 ,2 ]
Pandelaki, Jacub [2 ,3 ]
Ibrahim, Fera [4 ]
Nelwan, Erni Juwita [1 ,2 ,5 ,6 ]
机构
[1] Univ Indonesia, Fac Med, Dept Internal Med, Jakarta, Indonesia
[2] Cipto Mangunkusumo Natl Gen Hosp, Jakarta, Indonesia
[3] Univ Indonesia, Fac Med, Dept Radiol, Jakarta, Indonesia
[4] Univ Indonesia, Fac Med, Microbiol Dept, Jakarta, Indonesia
[5] Univ Indonesia, Fac Med, Dept Internal Med, Div Trop & Infect Dis, Jakarta, Indonesia
[6] Univ Indonesia, Infect Dis & Immunol Res Ctr IMERI, Fac Med, Jakarta, Indonesia
关键词
D O I
10.1155/2021/9673453
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. Conclusion. We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] COVID-19 mRNA Vaccine-Associated Autoimmunity Presenting as Minimal Change Disease and Membranous Nephropathy
    Jhaveri, Kenar D.
    Bijol, Vanesa
    Wanchoo, Rimda
    Keller, Keith H.
    Alexander, Mariam P.
    Weins, Astrid
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 94 - 94
  • [32] The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review
    Cherif, Yasmine Yousra Sadok
    Djeffal, Chakib
    Abu Serhan, Hashem
    Elnahhas, Ahmed
    Yousef, Hebatallah
    Katamesh, Basant E.
    Abdelazeem, Basel
    Abdelaal, Abdelaziz
    VACCINES, 2023, 11 (01)
  • [33] Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review
    Chua, Tzy Harn
    Takano, Angela
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [34] Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink
    Boyce, Thomas G.
    Mcclure, David L.
    Hanson, Kayla E.
    Daley, Matthew F.
    Desilva, Malini B.
    Irving, Stephanie A.
    Jackson, Lisa A.
    Klein, Nicola P.
    Lewin, Bruno
    Williams, Joshua T. B.
    Duffy, Jonathan
    Mcneil, Michael M.
    Weintraub, Eric S.
    Belongia, Edward A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (08)
  • [35] Clinical Features of COVID-19 Vaccine-Associated Autoimmune Hepatitis: A Systematic Review
    Zhou, Hao
    Ye, Qing
    DISEASES, 2023, 11 (02)
  • [36] Messenger RNA COVID-19 Vaccine-Associated Collapsing Focal and Segmental Glomerulosclerosis
    Jweehan, Duha A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 509 - 509
  • [37] A report on neurogenic bladder in COVID-19 vaccine-associated acute transverse myelitis
    Zainudin, Muhamad Faizal
    Hasim, Mohd Razali
    Martin, Christina Eleanor
    Chandrabose, Thanalactchumy
    SPINAL CORD SERIES AND CASES, 2024, 10 (01)
  • [38] COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey
    Yoo, Hongseok
    Kim, Song Yee
    Park, Moo Suk
    Jeong, Sung Hwan
    Park, Sung-Woo
    Lee, Hong Lyeol
    Lee, Hyun-Kyung
    Yang, Sei-Hoon
    Jegal, Yangjin
    Yoo, Jung-Wan
    Lee, Jongmin
    Kang, Hyung Koo
    Choi, Sun Mi
    Park, Jimyung
    Kim, Young Whan
    Song, Jin Woo
    Park, Joo Hun
    Choi, Won-Il
    Choi, Hye Sook
    Park, Chul
    Park, Jeong-Woong
    Chung, Man Pyo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (14)
  • [39] A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barre Syndrome
    Hilts, Alexis
    Schreiber, Ariyon
    Singh, Aditi
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [40] COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients
    Elnahry, Ayman G.
    Al-Nawaflh, Mutaz Y.
    Eldin, Aisha A. Gamal
    Solyman, Omar
    Sallam, Ahmed B.
    Phillips, Paul H.
    Elhusseiny, Abdelrahman M.
    VACCINES, 2022, 10 (10)